Zepbound is described as a dual agonist because it activates both the GIP and GLP-1 receptors simultaneously
A plan may prefer one medication, require less documentation for one, or apply different step-therapy rules
A: The Bridge applies to eligible Medicare Part D enrollees who are prescribed a GLP-1 specifically for obesity treatment
These treatments are recommended alongside dietary adjustments and physical activity
Kastenmller received funding (through their institutions) from the National Institutes of Health/National Institute on Aging through grants RF1AG058942, RF1AG059093, U01AG061359, U19AG063744, R01AG069901, and R01AG081322
These roles are thought to be linked to its influence on signaling pathways such as those involving Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor beta (TGF-)